Figure 3.

Evaluation of the Bystander Killing Effect of CRISPR/Cas9-Modified hAMSCs In Vitro

(A) Representative bright-field images of single Pluc-EGFP-U87, and co-cultures with either control hAMSCs or EGFP-tTK-hAMSCs at days 0, 3, and 6 of GCV treatment. Scale bars, 20 μm. (B) Graph showing the fraction of Pluc-EGFP-U87 cells surviving GCV treatment. Tumor cells were mixed at ratio 1:4 with control hAMSCs or with EGFP-tTK-hAMSCs and treated with GCV (4 μg/mL). **p < 0.01; ***p < 0.001 compared with the control group. Error bars represent mean ± SD.